GlobeNewsWire
16 Jun 2026, 17:49 UTC · 14w ago
Verdict
Headline takes no side. We score NTHI +0.80 across five claims — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
NeOnc's NEO100 program has achieved full enrollment in its Phase 2a study for recurrent IDH1-mutant high-grade glioma, with top-line data expected in late 2026.
More positive than 99% of claims this week
The Department of Health – Abu Dhabi has granted Investigational New Drug (IND) authorization for NEO212 to treat aggressive brain tumors.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More positive than 86% of claims this week
CEO Amir Heshmatpour has purchased over $500,000 in open-market stock in recent weeks, with total annual insider purchases approaching $1 million.
So whatSignificant open-market buying by the CEO typically signals strong management confidence in upcoming catalysts and company valuation.
More positive than 78% of claims this week
NeOnc has established a recommended Phase 2 dose of 610 mg for NEO212 following the completion of its Phase 1 dose-escalation study.
More positive than 65% of claims this week
The company maintains financial flexibility through a $75 million at-the-market facility and a $10 million line of credit.
So whatAvailable liquidity reduces immediate dilution risk and provides the runway needed to reach upcoming clinical data readouts.
More positive than 52% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company received IND authorization in Abu Dhabi, reached full enrollment in a Phase 2a study with encouraging clinical observations, and has seen significant insider buying by the CEO.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
7h ago
−26.6%
Price is moving against the score
$3.31 vs $4.51 close before publication (Jun 15) · not market-adjusted
NTHI chart →
